Progression of Symptoms
Our research showed that there is very little difference between early symptoms and ongoing, chronic symptoms. But the experience of dealing with these symptoms and the impact it has on patients' lives are often different.
Early Experience
Most people with Gadolinium Toxicity from contrast MRIs have symptoms within the first month after their contrast administration. For many, their symptoms start within a few days, and for some, within hours of being injected with the contrast agent. Usually the symptoms are intense, but for some the symptoms are more subtle. The experience can be frightening because the feelings are new and different; often, nothing is visible on the outside of the body. One's mental or emotional state can be affected.
Generally, the intensity of the symptoms will subside over time, but the reduction is not necessarily uniform, with ups and downs. The frightened feeling also dissipates with time, and the symptoms may feel less intense as the mind and body get used to dealing with them. Reading some of the Viewpoints from people who have gone through this might be helpful and joining the MRI Gadolinium Support Group can provide interactive support.
Longer Term Chronic Experience
With time, symptoms may go away or significantly subside, but patients reported on in our Survey of the Chronic Effects of Retained Gadolinium from Contrast MRIs, have been dealing with their chronic symptoms for up to 5 years with no end in sight. With little medical attention, there are no known treatments to "cure" Gadolinium Toxicity (read more in Treatments). Symptom relief and coping methods will most often bring the patient into a state of being able to tolerate or simply accept their symptoms.
As anyone dealing with chronic conditions, patients experience ups and downs, and often try a variety of approaches to lessen the impact of their symptoms. For those whose symptoms do not go away, the intensity of the symptoms may increase over time. This would seem to indicate that the Gadolinium Toxicity is continuing to negatively impact their body.
It is much harder to describe the chronic experience because each of our bodies is different and our ability to cope is different. Since nothing has been published about patients with normal kidney function who developed NSF, we do not know if anyone with normal kidney function has died from their exposure to Gadolinium-Based Contrast Agents. We are also not aware of anyone who has "cured" their Gadolinium Toxicity, although some on the MRI Gadolinium Support Group have reported improvement of some symptoms after trying various treatments. Some have been diagnosed with Small Fiber Sensory Neuropathy, thyroid abnormalities, adrenal fatigue, mast cell problems and other conditions. Often these diagnoses indicate some sort of atypical presentation of the associated symptoms. Since no related medical research has been published, we have no way of knowing whether there is a connection between the Gadolinium Toxicity and these conditions.
Our best advice is to hang in there and look for those actions that will help you deal with your symptoms and make sure your doctors know what you are experiencing. We would be happy to have you join the MRI Gadolinium Support Group to pass on your experience and learn from others.
Early-Phase NSF Symptoms
According to Marckmann & Skov (2009), "skin changes and neuropathic symptoms predominate the early phase of NSF." The early phase ranged from 14 to 60 days after GBCA exposure, with an intermediate phase of 60 to 180 days.
- •Skin changes - Rash, erythema, skin discoloration, itching, burning sensations, swelling
- •Neuropathic symptoms - 80% of patients complained of pain, dysesthesia (burning, itching, electric-shock sensations), or hyperalgesia (increased sensitivity to pain)
- •Muscle weakness complaints are common
- •Deep bone pain in the hips and ribs
- •Diffuse hair loss in up to 50% of patients
- •Acute gastroenteritis discomfort with pain, vomiting, and diarrhea
- •Red eyes as signs of noninfectious conjunctivitis in 20% or more
- •Acute pneumonia symptoms in 15%, including shortness of breath, hypoxia
- •Signs of systemic inflammation with fever, elevated C-reactive protein, elevated ferritin, anemia
Research Abstract
The U.S. Food & Drug Administration (FDA) has acknowledged that after MRIs with a gadolinium-based contrast agent (GBCA), patients retain an unknown amount of gadolinium (Gd) in the brain, bone, skin, and other tissues, where it can remain for months to years. Although Gd is a toxic metal recognized as the primary cause of nephrogenic systemic fibrosis (NSF), harm attributed to long-term Gd retention in patients with normal renal function has not been recognized.
Results: From a list of 60 symptoms, 19 of the 28 most frequently reported symptoms of the NSF Group were also ranked among the top symptoms reported by two groups of Gd-exposed patients without renal impairment, indicating a substantial overlap in clinical presentation between what has been published about early-phase NSF and the post-GBCA symptom complex. Eleven of the 19 most frequently reported symptoms involve the nervous system.
Conclusion: These observations are consistent with the hypothesis that gadolinium exposure is associated with a spectrum of manifestations and underscore the need for standardized recognition, systematic clinical assessment, and further objective study of Gd-associated multisystem symptoms in all patient populations.
Sources and Review
Author: Gadolinium.org Editorial Team (Patient-Led Education)
Last reviewed: February 21, 2026
Medical review context: Reviewed against published patient-survey findings and physician-linked educational sources on this page.
This page is for education only and is not a diagnosis or treatment plan.